R. Borie (Paris, France), M. Kokosi (London, United Kingdom)
A characterisation of patients with Antisynthetase Syndrome>
E. Heiden (Portsmouth, United Kingdom), V. Titmuss (Portsmouth, United Kingdom), S. Babu (Portsmouth, United Kingdom)
|   |
Radiological and clinical specific features of anti-synthetase syndrome : a retrospective analytic study
Q. Maloir (Liège, Belgium), F. Gester (Liège, Belgium), J. Corhay (Liège, Belgium), R. Louis (Liège, Belgium), J. Guiot (Liège, Belgium)
| |
Prognostic impact and clinical characteristics of Interstitial Pneumonia with Autoimmune features (IPAF) in a multidisciplinary setting
C. La Carrubba (PAVIA, Italy), L. Cavagna (PAVIA, Italy), E. Marasco (PAVIA, Italy), G. Zanframundo (PAVIA, Italy), A. Valentini (PAVIA, Italy), V. Morandi (PAVIA, Italy), V. Codullo (PARIS, France), L. Volpiano (PAVIA, Italy), F. Motta (PAVIA, Italy), C. Montecucco (PAVIA, Italy), F. Meloni (PAVIA, Italy)
| |
Analysis of multicentric Castleman’s disease with pulmonary involvement: A single center study
M. Amano (Saitama, Japan), H. Ohta (Saitama, Japan), G. Kida (Saitama, Japan), Y. Tsukahara (Saitama, Japan), E. Tsumiyama (Saitama, Japan), K. Kusano (Saitama, Japan), T. Nishizawa (Saitama, Japan), T. Ohba (Saitama, Japan), H. Yamakawa (Saitama, Japan), R. Kawabe (Saitama, Japan), S. Sato (Saitama, Japan), K. Akasaka (Saitama, Japan), H. Matsushima (Saitama, Japan)
| |
Pulmonary light chain deposition disease: a retrospective analysis of 11 cases
M. Baqir (Rochester, United States of America), T. Moua (Rochester, United States of America), D. White (Rochester, United States of America), R. Jay (Rochester, United States of America)
| |
Lung involvement in common variable immunodeficiency (CVID): a case series
A. Alves Moreira (Lisboa, Portugal), C. Lopes (Lisboa, Portugal), N. Melo (Porto, Portugal), H. Bastos (Porto, Portugal), P. Mota (Porto, Portugal), A. Morais (Porto, Portugal)
| |
Pleuroparenchymal fibroelastosis - clinical analysis of 22 cases
J. Pires Parreira (Guarda, Portugal), C. Santos (Guarda, Portugal), M. Oliveira (Guarda, Portugal), N. Melo (Porto, Portugal), P. Mota (Porto, Portugal), H. Bastos (Porto, Portugal), J. Pereira (Porto, Portugal), C. Souto Moura (Porto, Portugal), A. Morais (Porto, Portugal)
| |
Clinical and pathological features of idiopathic and secondary pleuroparenchymal fibroelastosis in patients undergoing lung transplantation
N. Ikegami (Kyoto, Japan), N. Nakajima (Kyoto, Japan), K. Tanizawa (Kyoto, Japan), A. Yoshizawa (Kyoto, Japan), T. Handa (Kyoto, Japan), T. Chen-Yoshikawa (Kyoto, Japan), T. Kubo (Kyoto, Japan), A. Osumi (Kyoto, Japan), Y. Yamada (Kyoto, Japan), M. Hamaji (Kyoto, Japan), D. Nakajima (Kyoto, Japan), Y. Yutaka (Kyoto, Japan), S. Tanaka (Kyoto, Japan), K. Watanabe (Kyoto, Japan), Y. Nakatsuka (Kyoto, Japan), Y. Murase (Kyoto, Japan), T. Nakanishi (Kyoto, Japan), T. Niwamoto (Kyoto, Japan), K. Chen (Kyoto, Japan), H. Date (Kyoto, Japan), T. Hirai (Kyoto, Japan)
| |
The natural history of Pulmonary Alveolar Proteinosis (PAP): data from the Italian National Reference Center
I. Campo (Pavia, Italy), S. Lettieri (Pavia, Italy), D. Piloni (Pavia, Italy), A. De Silvestri (Pavia, Italy), E. Salvaterra (Pavia, Italy), M. Zorzetto (Pavia, Italy), A. Corino (Pavia, Italy), F. Meloni (Pavia, Italy), F. Mariani (Pavia, Italy)
| |
Correlation between imaging fibrosis severity and bronchoalveolar lavage pattern in interstitial lung disease
B. Dhahri-Ourari (Tunis, Tunisia), R. Fessi (Tunis, Tunisia), H. Zaibi (Tunis , Tunisia), M. Ferchichi (Tunis, Tunisia), N. Guediri (Tunis, Tunisia), A. Jarrar (Tunis , Tunisia), J. Ben Amar (Tunis, Tunisia), H. Aouina (Tunis, Tunisia)
| |
Clinical features and outcome of adult patients with pulmonary Langerhans cell histiocytosis
E. Radzikowska (Warsaw, Poland), E. Wiatr (Warsaw, Poland), K. Blasinska-Przerwa (Warsaw, Poland), M. Jeskiewicz (Warsaw, Poland), R. Langfort (Warsaw, Poland), B. Maksymiuk (Warsaw, Poland), K. Modrzewska (Warsaw, Poland), I. Bestry (Warsaw, Poland), M. Zaleska (Warsaw, Poland), J. Szopinski (Warsaw, Poland), A. Jerzemska (Bydgoszcz, Poland), M. Ochman (Zabrze, Poland), W. Naumnik (Bialystok, Poland), D. Jastrzebski (Zabrze, Poland), W. Piotrowski (Lódz, Poland), K. Roszkowski-Sliz (Warsaw, Poland)
| |
Pulmonary Hypertension in Pulmonary Langerhans Cell Histiocytosis: prevalence and the role of Cardiopulmonary Exercise Testing and echocardiogram in predicting it
G. Itamaro Heiden (São Paulo, Brazil), J. Barbosa Sobral (São Paulo, Brazil), J. Alves Jr (São Paulo, Brazil), J. Salge (São Paulo, Brazil), A. Albuquerque (São Paulo, Brazil), C. Fernandes (São Paulo, Brazil), R. Kairalla (São Paulo, Brazil), C. Ribeiro Carvalho (São Paulo, Brazil), R. Souza (São Paulo, Brazil), B. Guedes Baldi (São Paulo, Brazil)
| |
Vascular endothelial growth factor (VEGF) is a predictable marker for FEV1 progression in patients with Lymphangiolyomyomatosis (LAM).
J. Freise (Hannover, Germany), M. Klingenberg (Hannover, Germany), J. Fuge (Hannover, Germany), T. Welte (Hannover, Germany)
| |
KCa3.1 ion channel is expressed by component cells of lymphangioleiomyomatosis (LAM) nodules
S. Naveed (Leicester, United Kingdom), D. Clements (Nottingham, United Kingdom), S. Johnson (Nottingham, United Kingdom), K. Roach (Leicester, United Kingdom), P. Bradding (Leicester, United Kingdom)
| |
Long-term sirolimus treatment in lymphangioleiomyomatosis
E. Revilla Lopez (Barcelona, Spain), C. Berastegui (Barcelona, Spain), B. Saez (Barcelona, Spain), A. Mendez (Barcelona, Spain), M. Lopez Meseguer (Barcelona, Spain), I. Sansano (Barcelona, Spain), S. Gomez Olles (Barcelona, Spain), A. Roman (Barcelona, Spain)
| |
Subclinical right ventricular dysfunction in fibrotic interstitial lung diseases: a combined assessment by speckle tracking and three-dimensional echocardiography
A. Canora (Naples, Italy), A. Buonauro (Naples, Italy), P. Dolce (Naples, Italy), C. Nicoletta (Naples, Italy), G. Ghinassi (Naples, Italy), E. Ciasullo (Naples, Italy), A. Sanduzzi Zamparelli (Naples, Italy), M. Galderisi (Naples, Italy), M. Bocchino (Naples, Italy)
| |